2 citations
,
January 2014 in “Journal of the American Academy of Dermatology” Topical minoxidil effectively promotes hair regrowth in male pattern baldness.
4 citations
,
July 2018 in “PubMed” Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.
36 citations
,
November 2020 in “Journal of The European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
59 citations
,
March 2003 in “The Lancet” Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
1 citations
,
February 2022 in “JAMA Dermatology” Minoxidil and finasteride are FDA-approved treatments for male hair loss, but off-label use of oral minoxidil, dutasteride, and higher doses of finasteride and minoxidil is increasing.
New therapies like JAK inhibitors, PRP, and stem cell treatments show promise for better alopecia management.
June 2024 in “American Journal of Biomedical Science & Research” TH07 effectively promotes hair regrowth in androgenic alopecia with high patient satisfaction and no major side effects.
Minoxidil sulfate, delivered through iontophoresis, can be used to treat hair loss.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
April 2025 in “BMC Immunology” Targeting SIRT1 with antisense oligonucleotides could be a promising treatment for hair loss.